



HAL
open science

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients

J. Kattan, F. E. Karak, F. Farhat, D. A. Gerges, W. Mokaddem, G. Chahine, S. Khairallah, N. Fakhruddin, J. Makarem, F. Nasr

► To cite this version:

J. Kattan, F. E. Karak, F. Farhat, D. A. Gerges, W. Mokaddem, et al.. Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients. *BMC Cancer*, 2022, 22 (1), pp.1114. 10.1186/s12885-022-10206-1 . inserm-03990057

HAL Id: inserm-03990057

<https://inserm.hal.science/inserm-03990057>

Submitted on 15 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients

Joseph Kattan^{1,2*}, Fady el Karak^{1,2}, Fadi Farhat^{2,3}, Dany Abi Gerges⁴, Walid Mokaddem⁵, Georges Chahine^{1,2}, Saad Khairallah⁶, Najla Fakhruddin⁷, Jawad Makarem⁸ and Fadi Nasr⁹

Abstract

Background: This study aimed to report the prevalence of HER2-neu in newly diagnosed early or metastatic gastric cancer (GC) patients, to determine the percentage of patients achieving various IHC scores correlating with the ISH results and to establish a database for GC patients in Lebanon.

Methods: This was a national, multicenter, descriptive and cross-sectional study in patients with histologically confirmed early or metastatic GC newly diagnosed. All eligible patients underwent the IHC and ISH tests in a central laboratory. Demographics, medical history and histopathology data were collected.

Results: One hundred fifty-seven patients were included (mean age at diagnosis: 63 ± 14.1 years) during a 3.5 year period. The prevalence of HER2-neu over expression was 21% (95% CI: 15.3–27.4) using ICH and ISH. Agreement between IHC and ISH results was significantly substantial ($\kappa = 0.681$; p -value < 0.001). Over expressed HER2-neu status was significantly associated with high ECOG performance status only.

Conclusions: The prevalence of HER2-neu over expression in newly diagnosed early or metastatic GC patients seemed to be high in Lebanon. The database generated allows to monitor trends in the epidemiology and management of GC.

Keywords: Gastric cancer, HER2-neu, Immunohistochemistry (IHC), *In-situ* hybridization (ISH), Prevalence

Introduction

Gastric cancer (GC) is the fourth most common cause of cancer-related death in the world. More than one million cases of GC were diagnosed in 2020 globally, and 769,000 deaths were attributed to GC in the same year [1]. The prevalence of GC is two-fold higher in men compared to women and varies geographically, with a much higher prevalence in Eastern Asian and Eastern European countries [1]. In Lebanon, GC is responsible for approximately 2.2% of all cancer cases, 2.4% (incidence rate of 6.4 per

100,000) of all male cancers and 2% (incidence rate of 5.2 per 100,000) of all female cancers based on the 2016 National Cancer Registry estimates [2]. A recently published study from Lebanon found that GC accounted for 15.5% of all gastrointestinal cancer cases between 2001 and 2015 [3].

Most cases of GC will present with advanced disease at diagnosis and have a poor outcome [4, 5]. GC risk factors have been identified and include gender [6] socioeconomic status [7], dietary factors such as salt intake and tobacco, coffee and alcohol consumption [8–10], certain autoimmune disorders [11], hereditary and environmental factors [12, 13], *Helicobacter pylori* infection [9, 14, 15], and gastric surgery [16]. Several factors can predict poor

*Correspondence: jkattan62@hotmail.com

² Saint-Joseph University, Beirut, Lebanon

Full list of author information is available at the end of the article



prognosis in GC, such as older age, larger tumor size, lymphovascular invasion, and lymph node metastasis [17]. The human epidermal growth factor receptor 2 (HER2-neu, aka HER2) is overexpressed in up to 22% of GC patients [18], and is currently one of the three available biomarkers of response to targeted therapy in GC. HER2-neu has also emerged as a prognostic factor for poor outcomes, worse survival and a more aggressive disease in GC [19–21].

As for treatment, trastuzumab (Herceptin[®], F. Hoffmann-La Roche Ltd, Basel, Switzerland), is a humanized monoclonal antibody directed against HER2 that was approved in 2010 for use in metastatic GC tumors with HER2 overexpression in combination with chemotherapy. Trastuzumab remains the only approved treatment for GC that overexpresses HER2-neu and its use has led to significant improvements in survival [22, 23]. Other novel HER2-targeting therapies are currently under trial and are expected to be invaluable in facing the inevitable emergence of resistance to trastuzumab. Current practice guidelines recommend that HER2 status be assessed at diagnosis in all metastatic GC patients to provide ideal patient management [24]. HER2 status can be assessed through different modalities, such as immunohistochemistry (IHC), *in-situ* hybridization (ISH), and Next-Generation sequencing (NGS). IHC, the most commonly used technique, semi-quantitatively assesses the expression of the HER2 protein on the surface of tumor cells. HER2 protein levels can then be scored on a scale of 0–3+ and determined to be negative (scores of 0 and 1+), equivocal (score of 2+), or over-expressed (score of 3+). Alternatively, ISH employs DNA probes to reflect the level of HER2 gene amplification. DNA probes can be fluorescently labeled (fluorescence ISH (FISH)) or DNP-labelled coupled with centromeric probes with chromogenic detection (Dual SISH (BDISH)). Based on this, tumor overexpression of HER2 can be established through high protein levels (IHC 3+) or HER2 gene amplification (FISH/Dual SISH positive). The application of IHC as the first-line testing method allows the identification of patients with HER2-over expressed disease (3+) who are candidates for trastuzumab, and the exclusion of patients with HER2-negative disease (0/1+). In parallel, IHC 2+ tumor samples should be retested for amplification of the HER2 gene by FISH or Dual SISH to ensure that all patients who may benefit from trastuzumab are identified [24].

Given these considerations, an epidemiological study was designed to assess the prevalence of HER2-neu overexpression in newly diagnosed early or metastatic GC patients residing in Lebanon. It also aimed to determine the percentage of patients achieving various IHC scores correlating with the ISH results and to establish

a database for GC patients in Lebanon in terms of referral and treatment trends of GC, taking into consideration several prognostic factors, mainly HER2-neu status and disease stage.

Methods

Study design and study population

This national multicenter, descriptive, cross-sectional cohort study was conducted in Lebanon. Patients aged over 18 years with newly diagnosed and histologically confirmed early or metastatic GC were enrolled after having signed an informed consent. Exclusion criteria included the participation in interventional or observational studies within the last 30 days, pregnancy, lactation and age below 18 years old.

Study procedures

All eligible patients underwent both the IHC and ISH (FISH or BDFISH) tests in a central laboratory. All paraffin blocks for testing were sent from the medical centers to the central laboratory using a courier service after completion of a request form by the investigator. The form was sent to the central laboratory along with the paraffin block for testing. The result of the HER2-testing was directly sent to the investigator by the central laboratory using the same courier service and the delivery was done the next day.

Data sources

The patients' socio-demographic data (date of birth, gender, marital status, residency area, occupation) risk factors (weight, height and body mass index [BMI]), smoking habits, consumption of fatty foods and anti-oxidants and family history of GC) were collected on a case report form. The medical history of the patients were also recorded and included the following information: date of first GC symptom, date of diagnosis, concomitant diseases (especially *Helicobacter pylori* infection, gastroesophageal reflux disease [GERD], hereditary non-polyposis colorectal cancer [HNPCC] and pernicious anemia), history of cardiac or pulmonary diseases, type of gastric surgery, site of cancer, biopsy, x-ray and endoscopy results, blood sampling results (complete blood count, vitamin B12 deficiency and carcinoembryonic antigen (CEA) 19–9 status), HER2-neu status, Tumor, Node, Metastasis (TNM) staging, sites of metastasis, Eastern Cooperative Oncology Group (ECOG) performance status (PS), referral system and therapeutic decision.

Sample size and statistical analysis

The sample size was computed using the formula ($n = z^2pq/d^2$) where, the sample size (n) is equal to the

squared z-value of desired significance level (90%) multiplied by the expected prevalence of positive HER2-neu among GC cases (18.8% according to Xie et al. [25] and the expected absence of positive HER2-neu (81.2%) divided by the squared acceptable range for the prevalence under study ($d = 5\%$). Based on these calculations, a minimum sample of 170 participants was required.

Patients with complete outcome data were included in the final analysis. Data were analyzed using IBM SPSS, version 20.0 for Windows release (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). Data were summarized using means, standard deviations, medians and interquartile ranges for continuous variables, and frequency distribution for categorical variables. The association of HER2-neu status with demographic, clinical and pathological variables was examined using the Pearson chi-square or Fisher’s exact test as appropriate for categorical variables, and Student’s *t*-test for continuous variables. The association of HER2-neu status with categorical variables of more than two categories was studied using logistic regression. Receiver Operating Characteristic (ROC) curve was performed to check true positive rate against the false positive rate taking IHC as a screening test and ISH as the gold standard for diagnosis in the Lebanese population. Area under the curve (AUC) was the method used to test the accuracy of the test: an area of 1 represented a perfect test while an area of 0.5 represented a worthless test. A test was considered a good screening test if AUC was ≥ 0.8 . Additional analysis was performed to assess the level of agreement between the IHC and ISH results in predicating HER2-neu status using Cohen’s kappa coefficient according to Landis and Kosh’s classification, which is universally accepted (Table 1) [26]. A two-sided *p*-value < 0.05 was considered statistically significant.

Ethics consideration

This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practice (GPP). It was also approved by the ethics

committees of each of the participating centers (ethics committee named after participating centers), which were: Ain Wa Zein Hospital, Bellevue Medical Center, Middle East Institute of Health, Haykel Hospital, Hotel Dieu De France, Hammoud University Hospital, Mount Lebanon Hospital, Beirut Governmental University Hospital- Rafic Hariri Governmental Hospital, and Saint Joseph University. All participants completed an informed consent form before their enrollment. All data were analyzed anonymously.

Results

Socio-demographic characteristics and risk factors

Between 12 April 2011 and 15 September 2014, a total of 157 newly diagnosed patients (88 [56.1%] men) with histologically confirmed early or metastatic GC were enrolled from nine sites from all Lebanese governorates. The mean age was 63.0 ± 14.1 years and the majority ($n = 149$; 94.9%) of the patients were Lebanese with 82 (52.3%) patients living in Mount Lebanon and 88 (56.1%) in the urban areas across the country. Overall, 129 (82.8%) patients were married, 84 (53.5%) were not employed. As for the risk factors, 51 (32.5%) were smokers and the majority of the patients ($n = 64$, 40.8%) had a normal healthy weight (Table 2).

Patients’ medical history

History of digestive system diseases showed that 8 (5.1%) patients had GERD, 19 (12.1%) had *Helicobacter pylori* infections and 7 (4.5%) had pernicious anemia. No patients were reported to be previously suffering from HNPCC. Cardiac diseases were reported in 38 (24.2%) patients and pulmonary diseases in 5 (3.2%) patients. The participants also suffered from other diseases such as diabetes mellitus ($n = 23$, 14.6%) and hypertension ($n = 20$, 12.7%).

Gastric cancer characteristics

Most of the GC cases occurred in the cardia ($n = 45$, 28.7%), followed by the antrum ($n = 37$, 23.6%), fundus ($n = 22$, 14%) and lesser curvature ($n = 17$, 10.8%). Other GC sites included: body of the stomach ($n = 12$, 7.6%), pylorus / antrum pylorus ($n = 7$, 4.5%), greater curvature ($n = 6$, 3.8%), posterior wall ($n = 3$, 1.9%), anterior wall and circle ($n = 2$, 1.3% each). Moreover, cancer started in the esophagus ($n = 17$, 10.8%) and the duodenum ($n = 3$, 1.9%). The most common PS was ECOG 1 ($n = 102$, 65%), followed by 2 ($n = 35$, 22.3%). Abnormal levels of hemoglobin were reported in 73 (47%) patients and lymphocyte count in 29 (18.5%) patients. As for tumor characterization, endoscopy showed that 111 (70.7%) GC cases were penetrating while only 15 (9.6%) were protruding. Also, Stage

Table 1 Interpretation of kappa according to Landis and Kosh [27]

Kappa	Agreement
< 0	Less than chance agreement (poor)
0.01–0.20	Slight agreement
0.21–0.40	Fair agreement
0.41–0.60	Moderate agreement
0.61–0.80	Substantial agreement
0.81–0.99	Almost perfect agreement

Table 2 Socio-demographic characteristics and risk factors of the patients (N=157)

Characteristics	
Socio-demographics	
Gender, n(%)	
Men	88 (56.1%)
Women	69 (43.9%)
Age at diagnosis (years)	
Mean ± standard deviation	63.0 ± 14.1
Range: minimum; maximum	29; 89
Residency area, n(%)	
Rural	61 (38.9%)
Urban	88 (56.1%)
Missing	8 (5.1%)
Geographical distribution, n(%)	
Beirut	17 (10.8%)
Bekaa	24 (15.3%)
Mount Lebanon	52 (33.1%)
Nabatiyeh	2 (1.3%)
North	28 (17.8%)
South	20 (12.7%)
Risk factors	
Smoking, n(%)	
No	90 (57.3%)
Yes	51 (32.5%)
Missing	16 (10.2%)
Alcohol consumption, n(%)	
No	90 (81.9%)
Yes	51 (7.7%)
Missing	16 (10.3%)
Fatty food consumption, n(%)	
No	123 (78.3%)
Yes	28 (17.8%)
Missing	6 (3.8%)
Antioxidant consumption, n(%)	
No	149 (95.5%)
Yes	2 (1.3%)
Missing	5 (3.2%)
BMI categories, n(%)	
Underweight (< 18 kg/m ²)	8 (5.1%)
Normal healthy weight (18.5–24.9 kg/m ²)	64 (40.8%)
Overweight (25–29.9 kg/m ²)	43 (27.4%)
Obese (> 30 kg/m ²)	21 (13.4%)
Missing	21 (13.4%)
Family history, n(%)	
No	141 (89.8%)
Yes	4 (2.5%)
Missing	12 (7.6%)

Abbreviations: BMI Body mass index

IIIB (N=19; 12.1%) and Stage IV (n=76; 48.4%) were the most common GC stages. The most common site of metastasis was the liver in 25 (34.0%) patients. The majority of patients had tubular carcinoma (59%) while only 34 patients (31.7%) had Signet-ring cell carcinoma (Table 3).

Disease management

A total of 55 (35%) patients underwent surgery. Referral was mainly done by a gastroenterologist (n=46, 29.3%) and surgeon (n=44, 28%). Neoadjuvant therapy was proposed to almost half of the operated patients (n=26; 47.2%). Out of the 26 patients who received a neoadjuvant therapy, anthracycline-based triplets were given to 15 (58%) patients, docetaxel -based therapy was given to 9 (34.6%) patients. First-line trastuzumab was given to 10/79 (12.7%) patients.

HER2-Neu status

IHC results showed that 10 (6.4%) patients had a HER2-over expressed disease (+3), 75 (47.7%) patients with HER2-negative disease (0/1+) and 72 (45.9%) cases were equivocal (2+). In parallel, ISH identified 33 (21.0%) HER2-over expressed patients and 111 (70.7%) HER2-negative patients; 13 (8.3%) patients' results were non-contributive. Based on IHC and ISH results, 8 of 75 patients were found HER2-over expressed with a significantly substantial level of agreement between both techniques (kappa = 0.681; p-value < 0.001); the positive percent agreement was 66.67% and the negative percent agreement was 96.82%. IHC had a total of 72 equivocal results with 3 non-contributive ISH (Table 4). Considering ISH as the gold standard, 33 (21%) patients were found HER2-over expressed, with a HER2-neu prevalence of 21% (95% CI: 15.3–27.4) in the sample.

Finally, bivariate analysis showed that ECOG PS was the only factor significantly associated with HER2 status as ECOG PS scores 1 to 3 were less frequent while score 4 was more frequent in the HER2-over expressed patients compared with HER2-negative patients (score 1: 13% versus 53.2%; score 2: 3.2% versus 17.5%; score 3: 3.2% versus 6.5%; score 4: 1.9% versus 0.8%; p-value = 0.018). Other factors such as age, gender, family history, dietary and lifestyle habits (smoking, alcohol consumption, antioxidants, fatty foods and BMI), stages, GERD, *Helicobacter pylori* infections, pernicious anemia, presence of metastasis and treatment modalities were not significantly different between HER2-over expressed and HER2-negative patients.

Table 3 Gastric cancer characteristics (N= 157)

Characteristics	
ECOG status, n(%)	
0	0 (0%)
1	102 (65.0%)
2	35 (22.3%)
3	15 (9.6%)
4	4 (2.5%)
Missing	1 (0.6%)
Endoscopy results, n(%)	
Penetrating	111 (70.7%)
Protruding	15 (9.6%)
Miscellaneous	6 (3.8%)
Superficial	3 (1.9%)
Linitis	3 (1.9%)
Not applicable	15 (9.6%)
Not done	4 (2.5%)
CT scan results, n(%)	
Coeliac lymphadenopathy	28 (17.8%)
Liver metastasis	19 (12.1%)
Other metastasis (bone, lung, ovarian, etc.)	69 (43.9%)
No metastasis	30 (19.1%)
Missing	11 (7.0%)
Chest x-ray results, n(%)	
Normal	18 (11.5%)
Central infiltration	2 (1.3%)
Other	8 (5.1%)
Missing	129 (82.2%)
Laboratory results, mean ± standard deviation	
CA 19–9 (U/mL)	1,122.00 ± 2,493.00
CEA (ng/ml)	91.43 ± 419.01
Hemoglobin (g/dL)	11.50 ± 2.20
Red blood cells count (10 ¹² /L)	4.19 ± 0.76
White blood cells count (10 ⁹ /L)	7.30 ± 3.40
Platelets count (10 ⁹ /L)	334.00 ± 254.00
Lymphocytes count (%)	23.30 ± 12.90
Neutrophils count (%)	58.00 ± 21.50
Abnormal results, n(%)	
Hemoglobin	73 (46.5%)
Red blood cells	48 (30.6%)
Lymphocytes	29 (18.5%)
Neutrophils	26 (16.6%)
White blood cells	25 (15.9%)
Monocytes	19 (12.1%)
CA	14 (8.9%)
Eosinophils	14 (8.9%)
CEA	9 (5.7%)
Vitamin B12	6 (3.8%)
Basophils	5 (3.2%)
Gastric cancer stage, n(%)	
IA	3 (1.9%)

Table 3 (continued)

Characteristics	
IB	2 (1.3%)
II	33 (21.0%)
IIIA	12 (7.6%)
IIIB	19 (12.1%)
IV	76 (48.4%)
Not applicable	12 (7.6%)
Sites of metastases, n(%)	
Bone	5 (3.2%)
Brain	1 (0.6%)
Liver	25 (15.9%)
Lung	5 (3.2%)
NA	2 (1.3%)
No metastasis	79 (50.3%)
Other	40 (25.5%)
Histology results, n(%)	
Hepatoid adenocarcinoma	1 (0.6%)
Mucinous adenocarcinoma	7 (4.5%)
Other	19 (11.5%)
Papillary adenocarcinoma	3 (1.9%)
Signet-ring cell carcinoma	34 (21.7%)
Tubular adenocarcinoma, moderately differentiated	44 (28.0%)
Tubular adenocarcinoma, well differentiated	11 (7.0%)
Tubular adenocarcinoma, poorly differentiated	38 (24.2%)
Undifferentiated carcinoma	1 (0.6%)

Abbreviations: CA Cancer antigen, CEA Carcinoembryonic antigen, ECOG Eastern Cooperative Oncology Group

Discussion

The prevalence of HER2-neu overexpression in GC was 21% in the present study, as determined using the HER-2 measurement procedure (ICH and ISH). This finding is aligned with the literature from Western and developed countries. Earlier screening data from the ToGA study showed an overall rate of 22.1% HER2-positivity, with 23.6% and 23.9% described in Europe and Asia, respectively [18]. A more recent large multinational study of close to 5000 GC patients reported an overall prevalence of 14.2% HER2-over expression [28]. When looking at rates from individual countries, the prevalence of HER2-positivity found in the

Table 4 Equivocal IHC results versus ISH results

		ISH		
		Over expressed	Negative	Total
		n(%)	n(%)	n(%)
ICH ^a	Equivocal	21 (30.4%)	48 (69.6%)	69 (100%)

Abbreviations: IHC Immunohistochemistry, ISH In-situ hybridization

^a IHC had a total of 72 equivocal results with 3 non contributive ISH

present study was comparable to that of GC patients from France (20.2%), yet is superior to the rate of 12.8% and 12% described in Asia and Europe, respectively [28].

The variability of HER2 overexpression rates is evident in GC and incidence can vary from 4 to 53% [29]. A previous study retrospectively reported 16.2% HER2 overexpression in a population of GC patients from a single medical institution in Lebanon [30]. A lower rate of 10.3% HER2 overexpression was found in a prospective cohort study of 58 patients from a single Lebanese center [27]. Studies offering insight into HER2 prevalence among GC cases in the Middle East region in general, and Lebanon in particular, remain scarce [31, 32]. To the best of our knowledge, this study is the first multicentric effort to prospectively investigate the prevalence of HER2-neu overexpression in newly diagnosed early or metastatic GC patients residing in Lebanon specifically, as well as in Arab countries in general.

In our study, no significant association was found between HER2-overexpressed status and classical reported clinical, pathologic and prognostic factors (i.e. age, gender, family history, dietary and lifestyle habits (smoking, alcohol consumption, antioxidants, fatty foods and BMI), disease's stages, GERD, *Helicobacter pylori* infections, pernicious anemia, presence of metastasis and treatment modalities). This is in contrast to available literature, where higher rates of HER2-positivity were found among the male gender, older ages (compared to the lowest age percentiles), intestinal-type tumors, metastasis and advanced tumor stages, and prognosis, among other factors [19, 28]. Studies have also previously described the influence of different risk factors on the incidence of GC, namely gender [6] socioeconomic status [7], dietary factors such as salt intake and tobacco, coffee and alcohol consumption [8–10], *Helicobacter pylori* infection [9, 14, 15], and gastric surgery [16]. A small study conducted has identified the need to target such risk factors, namely weight, physical activity and healthy diet with limited alcohol consumption, in public health interventions in order to reduce the risk of GC in the Lebanese population [33].

We otherwise report a significant correlation between HER2 overexpression and PS. This indicator is a simple clinical tool that can act as a surrogate marker for poor prognosis. Evidence shows that PS can independently reflect survival in advanced GC [34, 35]. Consistently, a meta-analysis of available literature identified a clear link between HER2-positivity and prognosis in GC [19], which could justify our findings seeing as both HER2 positivity and PS are associated with patient prognosis.

The incidence of *Helicobacter pylori* infections in patients diagnosed with GC in our study was 12%. This rate is substantially lower than those reported in other GC studies, where the incidence of *Helicobacter pylori*

infection can be as high as 94.40% [15]. *Helicobacter pylori* infection is clearly described as a risk factor for GC *via* mechanisms that not only include the development and progression of chronic gastritis and gastric tumors, but also the compromise of immunotherapy efficacy [36–39]. Globally, close to 90% of non-cardia GC cases are attributable to *Helicobacter pylori* [14]. The risk of *Helicobacter pylori* infections extends to both cardia and non-cardia GC patients in high-risk settings [15]. This notable discrepancy between the incidence of *Helicobacter pylori* infections in our study and relevant literature brings into question the etiology and pathogenesis of GC in Lebanon, which remains unclear and should be explored.

GC is a highly heterogenous disease and caution is advised when assessing HER2 status, particularly when determined with IHC [40]. Several protocols were placed to promote reproducibility of HER2 testing in GC in light of the technical, tumor-related, sample-related and interpretation-related issues faced in this context. While ISH might still be considered the gold standard of HER2 testing, IHC was shown to have higher diagnostic accuracy [41]. The agreement between IHC and ISH results was found to be significantly substantial in this study. IHC can be considered as a good screening test in our population given that plotting ROC gave a good discrimination of the IHC test (AUC=0.817; p -value=0.01). A systematic review and meta-analysis of available evidence also showed good concordance between HER2 IHC and ISH in GC [41]. To note that this concordance was limited to HER2 IHC score 0/1+ or 3+, suggesting the need for more detailed criteria in score 2+ [41]. Regardless of the agreement between ISH and IHC testing, one study noted that clinicians might consider conducting both IHC and ISH due to the improbability of consistent HER2 staining and laboratory results in the same community [42].

One limitation of the present study is the possibility of a classification bias with self-reported risk factors. As such, smoking, alcohol and fatty foods consumption could be underestimated. In parallel, the main strength point of the study is that HER2-neu status was tested according to a standardized protocol. Also, the study sample was chosen from nine centers in Lebanon and the patients were enrolled from all the Lebanese governorates with similar distribution to Lebanese population. In addition, we believe that these centers caught the majority of newly diagnosed cases of GC. Therefore, the results can be generalized to the Lebanese population.

Conclusions

To conclude and to the best of our knowledge, the present study is the first nationally representative study to provide data on the prevalence of HER2-neu overexpression in newly diagnosed early or metastatic GC patients

in Lebanon (21%). The study demonstrated a significantly substantial level of agreement between the ICH and ISH results. Such information is essential for the management of GC in the country as it allows to identify candidates who stand to achieve clinical benefit from anti-HER2-neu therapy and to avoid unwarranted treatment of those unlikely to respond.

Abbreviations

AUC: Area Under the Curve; BMI: Body Mass Index; CEA: Carcinoembryonic Antigen; CI: Confidence Interval; ECOG: Eastern Cooperative Oncology Group; FISH: Fluorescence In-situ hybridization; GC: Gastric Cancer; GERD: Gastroesophageal Reflux Disease; GPP: Good Pharmacoepidemiology Practice; HER2-neu (aka HER2): Human Epidermal Growth Factor Receptor 2; HNPCC: Hereditary Non-Polyposis Colorectal Cancer; HR: Hazard Ratio; IHC: Immunohistochemistry; ISH: In-situ hybridization; NGS: Next-Generation Sequencing; PS: Performance Status; ROC: Receiver Operating Characteristic; TNM: Tumor, Node, Metastasis.

Acknowledgements

The authors thank the study staff and all participants. The authors thank ClinArt MENA for providing data management and analysis services. Medical writing support was provided by Racha Aaraj, Pharm D, MSc, MPH and Nancy Al Akkary, MSc, BSc from Phoenix Clinical Research, Lebanon.

Authors' contributions

All authors were involved in the conception of the study and the interpretation of results. All authors participated in the development of this manuscript all authors read and approved the final manuscript.

Funding

This study was sponsored and funded by Hoffmann-La Roche Ltd., Lebanon.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practice (GPP). It was also approved by the ethics committees of each of the participating centers (ethics committee named after participating centers), which were: Ain Wa Zein Hospital, Bellevue Medical Center, Middle East Institute of Health, Haykel Hospital, Hotel Dieu De France, Hammoud University Hospital, Mount Lebanon Hospital, Beirut Governmental University Hospital- Rafic Hariri Governmental Hospital, and Saint Joseph Hospital. All participants completed an informed consent form before their enrollment. All data were analyzed anonymously.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Hôtel-Dieu de France University Hospital, Beirut, Lebanon. ²Saint-Joseph University, Beirut, Lebanon. ³Department of Hematology and Oncology, Hammoud Hospital University Medical Center, Saida, Lebanon. ⁴Department of Hematology and Oncology, Middle East Institute of Health, Bsalm, Lebanon. ⁵Department of Hematology and Oncology, Haykal Hospital, Tripoli, Lebanon. ⁶National Institute of Pathology, Baabda, Lebanon. ⁷Department of Pathology, Hammoud Hospital, Saida, Lebanon. ⁸Department of Hematology and Oncology, Ain W Zain Hospital, Ain W Zain, Lebanon. ⁹Department of Hematology and Oncology, Mount Lebanon Hospital, Beirut, Lebanon.

Received: 24 March 2022 Accepted: 19 September 2022
Published online: 01 November 2022

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71:209–49.
- MOPH. National Cancer Registry (NCR). 2016. <https://moph.gov.lb/en/DynamicPages/index/8/19526/national-cancer-registry>.
- Antoine AR, Joyce S, Joanna S, Christine K, Khoury Salem E, Philippe S. Gastrointestinal cancer characteristics in Lebanon. *Arab J Gastroenterol.* 2022;23:52–7.
- Thrift AP, Nguyen TH. Gastric Cancer Epidemiology. *Gastrointest Endosc Clin N Am.* 2021;31:425–39.
- Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC, et al. Survival outcomes of management in metastatic gastric adenocarcinoma patients. *Sci Reports* 2021 111. 2021;11:1–9.
- Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. *BMJ Open.* 2020;10:e033323.
- Sarkar S, Dauer MJ, In H. Socioeconomic Disparities in Gastric Cancer and Identification of a Single SES Variable for Predicting Risk. *J Gastrointest Cancer.* 2022;53:170–8.
- Martimianaki G, Bertuccio P, Alicandro G, Pelucchi C, Bravi F, Carioli G, et al. Coffee consumption and gastric cancer: a pooled analysis from the Stomach cancer Pooling Project consortium. *Eur J Cancer Prev.* 2022;31:117–27.
- Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaff F. Risk factors for stomach cancer: a systematic review and meta-analysis. *Epidemiol Health.* 2020;42:e2020004.
- Deng W, Jin L, Zhuo H, Vasiliou V, Zhang Y. Alcohol consumption and risk of stomach cancer: a meta-analysis. *Chem Biol Interact.* 2021;336:109365.
- Zádori N, Szakó L, Vánca S, Vörhendi N, Oštarijaš E, Kiss S, et al. Six autoimmune disorders are associated with increased incidence of gastric cancer: a systematic review and meta-analysis of half a million patients. *Front Immunol.* 2021;12:750533.
- Jin G, Lv J, Yang M, Wang M, Zhu M, Wang T, et al. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study. *Lancet Oncol.* 2020;21:1378–86.
- Yusefi AR, Lankarani KB, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: a systematic review. *Asian Pac J Cancer Prev.* 2018;19:591.
- Plummer M, Franceschi S, Vignat J, Forman D, De Martel C. Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J cancer.* 2015;136:487–90.
- Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with *Helicobacter pylori* infection in China: a case-cohort study. *Lancet Public Heal.* 2021;6:e888–96.
- Castagneto-Gissey L, Casella-Mariolo J, Casella G, Mingrone G. Obesity surgery and cancer: what are the unanswered questions? *Front Endocrinol (Lausanne).* 2020;11:213.
- Alshehri A, Alanezi H, Kim BS. Prognosis factors of advanced gastric cancer according to sex and age. *World J Clin Cases.* 2020;8:1608.
- Van Cutsem E, Bang YJ, Feng-yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer.* 2015;18:476.
- Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. *World J Surg Oncol.* 2017;15:68.
- Wang Y, He L, Cheng Y. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis. *Clin Transl Oncol.* 2018;20:212–20.
- Li H, Li L, Zhang N, Wang Z, Xu N, Linghu E, et al. Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up. *BMC Gastroenterol.* 2022;22:1–7.

22. Kim TH, Do Cho H, Choi YW, Lee HW, Kang SY, Jeong GS, et al. Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data. *BMC Cancer*. 2021;21:1–8.
23. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet (London, England)*. 2010;376:687–97.
24. Nicole McMillan N, Lenora Pluchino MA, Ajani JA, D TA, Chair V, Bentrem DJ, et al. NCCN Guidelines Version 2.2022 Gastric Cancer. 2022.
25. Xie SD, Xu CY, Shen JG, Jiang ZN, Shen JY, Wang LB. HER 2/neu protein expression in gastric cancer is associated with poor survival. *Mol Med Rep*. 2009;2:943–6.
26. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med*. 2005;37:360–3.
27. Mukherji D, Salim Hammoud M, Charafeddine M, Temraz S, Shamseddine A. Evaluation of morphology, HER2 status and its clinical and prognostic correlation in advanced gastric cancer: a prospective study at a tertiary referral center in Lebanon. *Ann Oncol*. 2017;28:iii35.
28. Kim W-H, Gomez-Izquierdo L, Vilardell F, Chu K-M, Soucy G, dos Santos LV, et al. HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. *Appl Immunohistochem Mol Morphol*. 2018;26:239–45.
29. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. *Int J cancer*. 2012;130:2845–56.
30. Assi T, El Rassy E, Khazzaka A, Moussa T, Ibrahim T, Kattan C, et al. Characteristics of gastric cancer in Lebanon: a descriptive study from a single institutional experience. *J Gastrointest Cancer* 2016 491. 2016;49:21–4.
31. Aoude M, Mousallem M, Abdo M, Youssef B, Kourie HR, Al-Shamsi HO. Gastric cancer in the Arab World: a systematic review. *Rev EMHJ (WHO EMRO)*. 2022;28:521–31.
32. Ramazani Y, Mardani E, Najafi F, Moradinazar M, Amini M. Epidemiology of Gastric Cancer in North Africa and the Middle East from 1990 to 2017. *J Gastrointest Cancer*. 2021;52:1046–53.
33. Charafeddine MA, Olson SH, Mukherji D, Temraz SN, Abou-Alfa GK, Shamseddine AI. Proportion of cancer in a Middle eastern country attributable to established risk factors. *BMC Cancer*. 2017;17:1–11.
34. Dogan I, Karabulut S, Tastekin D, Ferhatoglu F, Paksoy N, Sakar B. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. *J Coll Physicians Surg Pak*. 2022;32:1014–9.
35. Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, et al. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. *Future Oncol*. 2021;17:4157–69.
36. Waskito LA, Rezkitha YAA, Vilaichone R, Sugihartono T, Mustika S, Dewa Nyoman Wibawa I, et al. The role of non-*Helicobacter pylori* bacteria in the pathogenesis of gastroduodenal diseases. *Gut Pathog*. 2022;14:19.
37. Pop R, Tăbăran A-F, Ungur AP, Negoescu A, Cătoi C. *Helicobacter Pylori*-induced gastric infections: from pathogenesis to novel therapeutic approaches using silver nanoparticles. *Pharmaceutics*. 2022;14:1463.
38. Zhu L, Huang Y, Li H, Shao S. *Helicobacter pylori* promotes gastric cancer progression through the tumor microenvironment. *Appl Microbiol Biotechnol*. 2022;106:4375.
39. Oster P, Vaillant L, McMillan B, Velin D. The Efficacy of Cancer Immunotherapies Is Compromised by *Helicobacter pylori* Infection. *Front Immunol*. 2022;13:899161.
40. Satala CB, Jung I, Stefan-Van Staden RI, Kovacs Z, Molnar C, Bara TB, et al. HER2 heterogeneity in gastric cancer: a comparative study ,using two commercial antibodies. *J Oncol*. 2020;2020:8860174.
41. Pyo JS, Sohn JH, Kim WH. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. *Int J Biol Markers*. 2016;31:e1-10.
42. Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, et al. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. *Am J Surg Pathol*. 2012;36:577–82.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

